Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.15
-0.3%
$3.54
$2.45
$4.14
$249.98M0.24374,204 shs238,752 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$4.85
-2.4%
$5.99
$3.79
$14.60
$266.27M-0.91.02 million shs739,124 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$9.81
-2.8%
$11.66
$8.46
$26.50
$255.06M0.3978,893 shs47,865 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.62
-2.5%
$0.68
$0.40
$0.94
$66.81M1.27198,995 shs183,891 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-2.77%-7.06%-6.51%-0.32%-13.90%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.55%-15.19%-17.44%-8.97%-22.83%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-0.98%+2.54%-4.18%-3.07%-23.09%
VolitionRx Limited stock logo
VNRX
VolitionRx
+4.26%-3.95%-0.78%+13.26%-2.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.15
-0.3%
$3.54
$2.45
$4.14
$249.98M0.24374,204 shs238,752 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$4.85
-2.4%
$5.99
$3.79
$14.60
$266.27M-0.91.02 million shs739,124 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$9.81
-2.8%
$11.66
$8.46
$26.50
$255.06M0.3978,893 shs47,865 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.62
-2.5%
$0.68
$0.40
$0.94
$66.81M1.27198,995 shs183,891 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-2.77%-7.06%-6.51%-0.32%-13.90%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.55%-15.19%-17.44%-8.97%-22.83%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-0.98%+2.54%-4.18%-3.07%-23.09%
VolitionRx Limited stock logo
VNRX
VolitionRx
+4.26%-3.95%-0.78%+13.26%-2.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0091.39% Upside
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.00
Buy$20.00311.86% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.80
Moderate Buy$40.00301.81% Upside
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50446.02% Upside

Current Analyst Ratings Breakdown

Latest VNRX, RNAC, CADL, and AVIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
9/3/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$13.00 ➝ $7.00
8/15/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
7/17/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/9/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/9/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy$23.00
6/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy$3.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$5.20 per shareN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,221.62N/AN/A$1.41 per share3.44
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$38.91M6.65N/AN/A($0.27) per share-36.87
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.32M52.28N/AN/A($0.11) per share-5.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.25N/AN/A-2,321.14%N/A-163.39%N/A

Latest VNRX, RNAC, CADL, and AVIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17-$0.09+$0.08-$0.09N/AN/A
8/7/2025Q2 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.46-$0.44+$0.02-$0.44N/AN/A
8/7/2025Q2 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.76$0.50+$1.26$0.50$0.77 million$0.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.17
19.17
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
7.04
7.04
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
13.33
13.33
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
60.30%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7079.36 million64.99 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6054.90 million45.78 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6426.00 million10.32 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80107.60 million80.80 millionOptionable

Recent News About These Companies

Volition Signs First Human Out Licensing Deal
Zacks Small Cap Estimates VolitionRx Q3 Earnings
Insights into VolitionRX's Upcoming Earnings
VolitionRx Limited (VNRX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.15 -0.01 (-0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$3.15 0.00 (0.00%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$4.85 -0.12 (-2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$4.88 +0.03 (+0.62%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$9.81 -0.28 (-2.78%)
Closing price 04:00 PM Eastern
Extended Trading
$9.82 +0.00 (+0.05%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.62 -0.02 (-2.53%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 +0.05 (+8.55%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.